韩国痛风患者 COVID-19 及其结局的风险：一项多中心、回顾性、观察性研究。
The Risk of COVID-19 and Its Outcomes in Korean Patients With Gout: A Multicenter, Retrospective, Observational Study.
机构信息
Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Korea.
Center for Data Science, Biomedical Research Institute, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Korea.
出版信息
J Korean Med Sci. 2024 Jan 29;39(4):e37. doi: 10.3346/jkms.2024.39.e37.
This retrospective cohort study aimed to compare coronavirus disease 2019 (COVID-19)-related clinical outcomes between patients with and without gout. Electronic health record-based data from two centers (Seoul National University Hospital [SNUH] and Boramae Medical Center [BMC]), from January 2021 to April 2022, were mapped to a common data model. Patients with and without gout were matched using a large-scale propensity-score algorithm based on population-level estimation methods. At the SNUH, the risk for COVID-19 diagnosis was not significantly different between patients with and without gout (hazard ratio [HR], 1.07; 95% confidence interval [CI], 0.59-1.84). Within 30 days after COVID-19 diagnosis, no significant difference was observed in terms of hospitalization (HR, 0.57; 95% CI, 0.03-3.90), severe outcomes (HR, 2.90; 95% CI, 0.54-13.71), or mortality (HR, 1.35; 95% CI, 0.06-16.24). Similar results were obtained from the BMC database, suggesting that gout does not increase the risk for COVID-19 diagnosis or severe outcomes.
本回顾性队列研究旨在比较伴有和不伴有痛风的 COVID-19 患者的临床结局。该研究基于电子健康记录，数据来源于 2021 年 1 月至 2022 年 4 月的两个中心（首尔国立大学医院[SNUH]和波拉美医院[BMC]），并映射到一个通用数据模型中。采用基于人群水平估计方法的大规模倾向评分算法对伴有和不伴有痛风的患者进行匹配。在 SNUH，COVID-19 诊断风险在伴有和不伴有痛风的患者之间无显著差异（风险比[HR]，1.07；95%置信区间[CI]，0.59-1.84）。在 COVID-19 诊断后 30 天内，住院（HR，0.57；95%CI，0.03-3.90）、严重结局（HR，2.90；95%CI，0.54-13.71）或死亡率（HR，1.35；95%CI，0.06-16.24）方面均无显著差异。BMC 数据库的结果相似，表明痛风不会增加 COVID-19 诊断或严重结局的风险。
Zotero 插件